A Universal Clinical Test for Gene Fusions in Blood Cancer

血癌基因融合的通用临床测试

• 批准号: nhmrc : 1108254
• 负责人: A/Pr Devinder Gill
• 金额: $ 43.14万
• 依托单位: Garvan Institute of Medical Research
• 依托单位国家: 澳大利亚
• 项目类别: Project Grants
• 财政年份: 2016
• 资助国家: 澳大利亚
• 起止时间: 2016-01-01 至 2018-12-31
• 项目状态: 已结题
• 来源: https://researchdata.edu.au/universal-clinical-test-blood-cancer/663032
• 关键词: Universal; Clinical; Test; Gene; Fusions

Mis-repair of broken chromosomes results in gene fusion and is a common feature of blood cancers. Current tests are only capable of detecting well-known gene fusions and are incapable of identifying new fusion events or fusion variations. We have developed a scientific technique, termed CaptureSeq, that can address these issues. We propose to use this technique as the foundation for a single clinical test for blood cancers, capable of detecting all possible fusion variations – known and unknown.

断裂染色体的错误修复导致基因融合，这是血癌的常见特征。目前的测试只能检测已知的基因融合，不能识别新的融合事件或融合变异。我们开发了一种名为CaptureSeq的科学技术，可以解决这些问题。我们建议使用这种技术作为血液癌症的单一临床测试的基础，能够检测所有可能的融合变异-已知和未知。